Active	Status	Sponsor type	Region	Phase	Filter
9 Active 0 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ghiaseddin, Ashley
EF-41, NCT06556563: /KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma	Recruiting	3	741	Japan, US	Optune® device, TTFields, Temozolomide, Pembrolizumab, Placebo	NovoCure GmbH, Merck Sharp & Dohme LLC	Glioblastoma	04/29	04/29
2-THE-TOP, NCT03405792: Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma	Active, not recruiting	2	40	US	Temozolomide (TMZ), Optune System, NovoTTF Therapy, Pembrolizumab, Keytruda	University of Florida, NovoCure Ltd.	Glioblastoma, Glioblastoma, WHO Grade IV	11/22	09/25
RENEW, NCT04963413: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.	Terminated	1	6	US	Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF	University of Florida, Immunomic Therapeutics, Inc.	Glioblastoma	09/23	09/23
Subramony, Sankarsubramone H
No trials found